MMP3 and familial pancreatic carcinoma: While early oncology trials of nonselective small molecule MMP inhibitors proved disappointing [11–13], it is likely that better results could be achieved by selective targeting of specific MMPs that contribute to tumor growth and malignant progression; our studies in breast, lung, and pancreatic cancer suggest that MMP3 may be a good candidate.